Status:
COMPLETED
NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL
Lead Sponsor:
Leiden University Medical Center
Collaborating Sponsors:
Novo Nordisk A/S
Herlev Hospital
Conditions:
Post Partum Hemorrhage
Eligibility:
FEMALE
18+ years
Brief Summary
The overall aim of this project is to include currently available information from women with severe postpartum haemorrhage (sPPH) who were treated with NovoSeven® and to examine whether NovoSeven® ma...
Detailed Description
This is a retrospective non-interventional cohort study of women with sPPH who were treated with NovoSeven® or other standard of care. The analyses will be done utilising data that were collected for ...
Eligibility Criteria
Inclusion
- \- Inclusion in one of the four cohorts (DK, FR, NL, UK)
Exclusion
- \- there are no exclusion criteria
Key Trial Info
Start Date :
May 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2021
Estimated Enrollment :
3322 Patients enrolled
Trial Details
Trial ID
NCT04723979
Start Date
May 1 2020
End Date
January 31 2021
Last Update
May 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leiden University Medical Center
Leiden, Netherlands, 2333 ZA